Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair® for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites

Osaka, Japan (February 16, 2018) – Shionogi & Co., Ltd. (hereafter “Shionogi”) has announced that the company got approval for the extension of indication for Actair®, a house dust mites sublingual tablet for allergen immunotherapy, to include treatment of patients with ages less than 12 years old in Japan with allergic rhinitis caused by house dust mites.

Allergen immunotherapy is the medical treatment in which patients are repeatedly administered appropriate dose of the antigen, allowing the immune reaction toward the allergen to alleviate. Sublingual type of allergen immunotherapy to house dust mites has been awaited, which can be taken at home by pediatric patients.

Actair® has been prescribed as allergen immunotherapy to adults and children aged 12 years or older since launched in November 2015. Now that Actair® has received approval for the additional indication of pediatric allergic rhinitis, it is expected to contribute to improve Quality of Life (QOL) for more patients including ages less than 12 years old.

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and well-being of the patients we serve.” Shionogi’s research and development currently targets two therapeutic areas: infectious diseases and pain/CNS disorders. A 139 year old company, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives for over 50 years. Contributing to the health and quality of life of patients around the world through development in these therapeutic areas is Shionogi’s primary goal. For more details, please visit http://www.shionogi.co.jp/en/.

Forward Looking Statement

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability

1 / 2
of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contacts:

Corporate Communications, Shionogi & Co., Ltd.
Telephone: +81-6-6209-7885
Fax: +81-6-6229-9596

##